Prana Biotechnology Limited (PBT.AX)

ASX - ASX Delayed Price. Currency in AUD
0.07-0.00 (-2.78%)
As of 7:53 PM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.07
Bid0.07 x
Ask0.07 x
Day's Range0.07 - 0.07
52wk Range0.06 - 0.15
1y Target EstN/A
Market Cap37.37M
P/E Ratio (ttm)-5.00
Avg Vol (3m)242,756
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Business Wire6 days ago

    New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting

    Prana Biotechnology Ltd is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster1 at the American Neurological Association Annual Meeting in Baltimore, United States.

  • Business Wire3 months ago

    Prana Alzheimer's disease data features at world leading conference

    Professor Rudolph Tanzi, Founding Scientist and Chief Scientific Advisor for Prana Biotechnology, presented results obtained from testing PBT2, Prana’s lead candidate for Huntington and Alzheimer’s diseases, at the Alzheimer’s Association International Conference in Toronto, Canada on July 26, 2016.

  • Five Stocks on the Move Today Amid a Mixed Market
    Insider Monkey4 months ago

    Five Stocks on the Move Today Amid a Mixed Market

    The US stock market is mixed, but relatively flat on Wednesday, following Federal Reserve Chairwoman Janet Yellen’s dovish message on interest rates, and ahead of tomorrow’s Brexit vote, which now seems like it will resolve toward a “Stay”. Among individual stocks, Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), Michael Kors Holdings Ltd (NYSE:KORS), Advanced Micro Devices, Inc. […]